Results 1 to 10 of about 332,782 (345)
Surfactant metabolic consequences of overexpression of GM-CSF in the epithelium of GM-CSF-deficient mice [PDF]
American Journal of Physiology-Lung Cellular and Molecular Physiology, 1997 Granulocyte macrophage colony-stimulating factor (GM-CSF) is a regulator of surfactant metabolism because GM-CSF-deficient mice have abnormally slow clearance and catabolism of saturated phosphatidylcholine (Sat PC) and surfactant protein (SP)-A in airspaces and lung tissue.
M, Ikegami +3 more
core +6 more sources
GM-CSF-Dependent Inflammatory Pathways [PDF]
Frontiers in Immunology, 2019 Pre-clinical models and clinical trials demonstrate that targeting the action of the cytokine, granulocyte macrophage-colony stimulating factor (GM-CSF), can be efficacious in inflammation/autoimmunity reinforcing the importance of understanding how GM-CSF functions; a significant GM-CSF-responding cell in this context is likely to be the monocyte ...
John A. Hamilton, John A. Hamilton
openaire +6 more sources
A bioluminescent inhibition immunoassay for detecting GM-CSF inhibitory activity in serum. [PDF]
Clin Exp ImmunolBradhurst P +5 more
europepmc +2 more sources
Journal of Experimental Medicine, 2019 Granulocyte–macrophage colony-stimulating factor (GM-CSF) has many more functions than its original in vitro identification as an inducer of granulocyte and macrophage development from progenitor cells. Key features of GM-CSF biology need to be defined better, such as the responding and producing cell types, its links with other mediators, its ...
openaire +2 more sources
The Journal of Immunology, 2017 With the cloning of the cDNA encoding murine GM-CSF in 1984, Dunn and colleagues ([1][1]) ushered the power of recombinant DNA technology into the exploration of the biology of this multifaceted cytokine.
openaire +2 more sources
GM-CSF and GM-CSF βc receptor in adult patients with pulmonary alveolar proteinosis [PDF]
European Respiratory Journal, 2000 Pulmonary alveolar proteinosis (PAP) is a rare disorder of unknown origin characterized by alveolar fillings with periodic acid-Schiff (PAS)-positive material mainly consisting of phospholipids. Mice defective in the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene or the GM-CSF/interleukin (IL)-3/IL-5-receptor common beta chain (beta c ...
B, Bewig +4 more
openaire +2 more sources
Thorax, 2003 The use of recombinant GM-CSF in the treatment of pulmonary alveolar proteinosis (PAP) has been reported recently in Thorax 1,2 in cases with anti-GM-CSF antibodies. We report the successful use of GM-CSF in a patient with no GM-CSF antibodies, which provides further evidence for considering GM-CSF as a possible keystone to the treatment of PAP.
openaire +1 more source
353TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01 [PDF]
, 2023 Snehal Patel +4 more
openalex +1 more source
G-CSF and GM-CSF in Neutropenia [PDF]
The Journal of Immunology, 2015 Abstract G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation.
Hrishikesh M, Mehta +2 more
openaire +2 more sources
Commanding CNS Invasion: GM-CSF [PDF]
Immunity, 2017 Granulocyte-macrophage colony-stimulating factor (GM-CSF or Csf-2) is a pro-inflammatory mediator implicated in the pathogenesis of various autoimmune diseases. In this issue of Immunity, Spath et al. (2017) show that the dysregulated production of GM-CSF rather than IL-17 induces spontaneous immunopathology in a mouse model of CNS inflammation.
Junjie, Zhao, Lillian, Sun, Xiaoxia, Li
openaire +2 more sources